Every material Form 8-K Research Alliance Corp IV has filed with the SEC since July 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Research Alliance Corporation IV, a blank check company, closed its initial public offering on July 14, 2026, selling 7,500,000 Class A ordinary shares at $10.00 each for $75 million in gross proceeds. The full $75 million was deposited in a trust account for public shareholders, and the company states it has not yet selected a business combination target. Public shareholders are entitled to redeem their shares from the trust account upon completion of a business combination.
Sold 7,500,000 Class A ordinary shares at $10.00 per share on July 14, 2026, for $75,000,000 gross proceeds.
Sponsor Research Alliance Holdings IV LLC bought 275,000 private placement shares for $2,750,000.
$75,000,000 deposited in trust account with Continental Stock Transfer & Trust Company as trustee; offering costs totaled $3,648,334.
Company has until July 14, 2028 to complete a business combination; no target has been selected.
Research Alliance Corporation IV, a blank check company focused on healthcare, closed its initial public offering on July 14, 2026, selling 7,500,000 Class A ordinary shares at $10.00 each for $75 million in gross proceeds. The IPO and a $2.75 million private placement to the sponsor funded a trust account of $75 million for public shareholders. The filing says the company must complete an initial business combination within 24 months of the IPO closing, or liquidate.
Closed IPO of 7,500,000 Class A ordinary shares at $10.00 per share on July 14, 2026, for gross proceeds of $75,000,000 before underwriting discounts and offering expenses.
Sponsor Research Alliance Holdings IV LLC bought 275,000 private placement shares at $10.00 each, for total proceeds of $2,750,000.
$75,000,000 of net proceeds and private placement funds, including a $2,250,000 underwriter deferred commission, were deposited in a trust account with Continental Stock Transfer & Trust Company as trustee.
Alan Musso and John Maslowski were appointed to the board on July 10, 2026, and each received 30,000 Class B ordinary shares from the sponsor as compensation.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Research Alliance Corp IV filing is on SEC EDGAR ↗. 8-K briefs of other companies →